跳至主要内容
临床试验/NCT01575730
NCT01575730已完成2 期

Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer

University Hospital, Ghent1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2012年5月21日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
45
试验地点
1
主要终点
Morbidity

研究概览

简要总结

Peritoneal carcinomatosis from appendix or colon (large bowel) cancer is treated in suitable patients with surgery followed by instillation of heated chemotherapy inside the abdominal cavity. This procedure is termed 'Hyperthermic intraoperative Peritoneal Chemoperfusion' or HIPEC. Many center perform HIPEC with high dose oxaliplatin, a standard chemotherapy drug active against colon cancer, administered during 30 minutes at 41°C. The hypothesis of this study is, that chemoperfusion at normal (37.5°C) temperature but longer duration (90 minutes) may be safer and at least as efficient. Patients will be treated with one of three possible HIPEC regimens using oxaliplatin: high dose, 30 min, 41°C; high dose, 30 min, 37.5°C; or low dose, 90 min, 37.5°C. The outcome parameters are pharmacokinetic and pharmacodynamic: using specialized techniques, tissue penetration of chemotherapy and cancer cell kill effects will be compared in order to establish the safest and most active HIPEC regimen.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with peritoneal carcinomatosis from colorectal origin (including appendiceal mucinous neoplasms and the pseudomyxoma syndromes) amenable for cytoreduction and HIPEC.

排除标准

  • No written informed consent
  • Irresectable and/or metastatic disease found during surgery
  • Known allergy to oxaliplatin

研究组 & 干预措施

Oxaliplatin 37°C, high dose, 30 minutes

Active Comparator

干预措施: Hyperthermic intraoperative Peritoneal Chemoperfusion (Drug)

Oxaliplatin 41 °C, high dose, 30 minutes

Placebo Comparator

干预措施: Hyperthermic intraoperative Peritoneal Chemoperfusion (Drug)

Oxaliplatin 37°C, low dose, 90 minutes

Active Comparator

干预措施: Hyperthermic intraoperative Peritoneal Chemoperfusion (Drug)

结局指标

主要结局

Morbidity

时间窗: Until discharge or within 30 days

Scoring of postoperative morbidity according to the Dindo-Clavien system

Mortality

时间窗: Until discharge or within 30 days

The number of deaths will be recorded.

Area under the plasma concentration versus time curve (AUC) of platinum

时间窗: Before addition of chemotherapy, at 10, 20, 30, 40, 50, 60, 70, 80, 90 minutes and 2, 4, 8, 12, 18, 24 hours after addition of chemotherapy

Measurements of platinum in plasma samples on the low dose intervention.

Area under the perfusate concentration versus time curve (AUC) of platinum

时间窗: Before addition of chemotherapy, at 10, 20, 30, 40, 50, 60, 70, 80 and 90 minutes after addition of chemotherapy

Measurements of platinum in perfusate samples on the low dose intervention.

次要结局

  • Tissue Concentration (Cmax) of Platinum(after 30 or 90 minutes)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验